Friday, July 24, 2026
← Back to archivePolicy
Policy•STAT News•Jul 24, 2026
Opinion: The U.S. pharmaceutical supply chain problem is not about China
background ▾
- •Pharmaceutical supply chain vulnerabilities are fundamentally a regulatory and infrastructure problem, not primarily a geopolitical one; inadequate FDA oversight and enforcement have directly caused major public health crises regardless of manufacturing location
- •Current policy emphasis on reducing China dependency through onshoring/friend-shoring will prove insufficient without concurrent investment in FDA capacity, transparency standards, and publicly funded research infrastructure
- •Watch for regulatory reform proposals in 2025; FDA staffing trends and any legislative changes to agency resources or standards-setting authority will signal whether policymakers accept this regulatory-first framing over geopolitical framing
BaxterNew England Compounding Centerheparinmethylprednisolone acetate
→ Read original articlePolicy•STAT News•Jul 24, 2026
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
background ▾
- •Unexpected bipartisan support for stricter food labeling and advertising restrictions, driven by MAHA momentum and changing Republican stance on food industry regulation
- •The Sanders bill proposes front-of-package warning labels modeled on Latin American systems plus first-of-kind beverage-specific warnings—substantively stronger than FDA's current 2025 proposal
- •Food industry and some Republicans argue labeling could increase costs; bill still faces significant obstacles to full Senate passage despite committee advancement
Policy•STAT News•Jul 24, 2026
Opinion: I may be one of the last middle-class medical students who could afford to become a doctor
background ▾
- •Federal loan policy changes eliminate Graduate PLUS borrowing for medical students, capping graduate loans while medical school costs remain unchanged—shifting barriers from affordability to access based on financial circumstances rather than merit.
- •Approximately 70% of U.S. medical graduates carry debt (median $215,000), and physicians from lower-income backgrounds disproportionately serve rural and underserved communities already facing critical shortages; restricting financing may exacerbate workforce maldistribution.
- •Medical schools are adjusting to new loan limits amid applicant uncertainty about borrowing capacity and financial aid timelines—monitor how schools respond, whether alternative financing emerges, and actual enrollment impacts on future physician supply and diversity.
Policy•Endpoints News•Jul 23, 2026
FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157
background ▾
- •FDA advisory committee recommended lifting restrictions on BPC-157, a wellness peptide with unproven clinical efficacy
BPC-157
→ Read original articlePolicy•Endpoints News•Jul 23, 2026
FDA to end pilot aimed at preventing production issues
background ▾
- •FDA pilot program for proactive manufacturing issue resolution is being terminated due to low participation rates
- •Limited industry adoption suggests the program may not have addressed real pain points or provided sufficient value to justify participation
Market Access
Market Access•Fierce Biotech•Jul 24, 2026
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
background ▾
- •Scribe raised $128.7M in IPO (plus $19.3M potential), exceeding guidance and pricing at top of range, signaling strong investor appetite for gene editing platforms in cardiometabolic disease
- •STX-1150 targeting PCSK9 enters Phase 1 in competitive landscape with approved PCSK9 inhibitors (Repatha, Leqvio) and newly approved oral alternative (Lipfendra); topline data not until H1 2027
- •Sanofi's $7.5M concurrent stock purchase signals continued confidence in partnership; watch for Phase 1 STX-1150 enrollment progress and potential competitive positioning vs. Merck's oral PCSK9 pill
Scribe TherapeuticsBiogenAmgenSTX-1150STX-1400STX-1200
→ Read original articleMarket Access•Fierce Biotech•Jul 23, 2026
Scancell to go public after winning reverse merger bid for troubled Neuphoria
background ▾
- •Scancell achieves Nasdaq listing via reverse merger and secures $89M financing to fund global phase 3 trial of iSCIB1+, an FDA fast-track designated melanoma immunotherapy with compelling phase 2 efficacy (77% PFS at 22 months)
- •Neuphoria shareholders obtain liquidity after strategic failures (soclenicant social anxiety trial failure, Merck termination of Alzheimer's program), with existing Neuphoria investors retaining only 14.5% of combined entity
- •Monitor phase 3 enrollment and interim efficacy readouts for iSCIB1+ combination therapy; additional phase 2 Scope study data expected later in 2026 will signal confidence in registrational path
Scancell HoldingsNeuphoria TherapeuticsBristol Myers SquibbiSCIB1+YervoyOpdivo
→ Read original articleMarket Access•Endpoints News•Jul 24, 2026
Gene editor Scribe starts second-half IPO spree with $129M listing
background ▾
- •Scribe Therapeutics IPO signals renewed investor appetite for gene editing biotechs despite recent market volatility
Scribe Therapeutics
→ Read original articleMarket Access•Endpoints News•Jul 23, 2026
Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales
background ▾
- •Leqembi sales trajectory has significantly underperformed post-launch expectations despite FDA approval, creating a material revenue gap for Biogen
- •Biogen is strategically dependent on Apellis-sourced drugs to offset commercial weakness in its lead Alzheimer's asset
- •The success of Biogen's portfolio strategy hinges on both Apellis pipeline efficacy and ability to reverse Leqembi adoption trends
BiogenEisaiApellisLeqembi
→ Read original articleMarket Access•Endpoints News•Jul 23, 2026
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion
background ▾
- •Repligen's $1.5B acquisition of BioLife Solutions represents major consolidation in bioprocess manufacturing, critical infrastructure for cell/gene therapy scale-up
- •Concurrent $300M US expansion by BeOne indicates robust demand for manufacturing capacity across the biotech sector
- •Watch for integration strategy, pricing implications for bioprocess tools, and competitive responses from other CDMO/manufacturing platform providers
RepligenBioLife SolutionsBeOne
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 24, 2026
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
background ▾
- •Sanofi abandons amlitelimab in AD after phase 3 trials fell short of Dupixent's efficacy bar, ending pursuit of a drug that was once viewed as a potential blockbuster from a $1.1B acquisition
- •Leadership transition under new CEO Garijo and incoming R&D head Paulo Fontoura (from Roche) is driving a strategic reassessment of the pipeline, resulting in the culling of underperforming programs
- •Watch for remaining amlitelimab development in celiac disease (phase 2b readout expected H2 2026) and Sanofi's broader pipeline prioritization under new R&D leadership
SanofiKymabRegeneronamlitelimabDupixent
→ Read original articleClinical Trials•Fierce Biotech•Jul 23, 2026
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
background ▾
- •Retatrutide met primary weight loss endpoints but at lower magnitude (20.8-22.6%) in diabetic/severely obese populations than in non-diabetic cohorts (28%+), suggesting patient population significantly impacts efficacy
- •TRIUMPH-3 cardiovascular outcome trial failed to show reduction in major adverse cardiovascular events (44 vs 52 in placebo), undermining potential differentiation and limiting clinical value proposition despite improvements in individual risk markers
- •Discontinuation rates increased to 13.5% in TRIUMPH-3 high-dose cohort versus 11.3% in TRIUMPH-1, with GI side effects (nausea 22.4%, diarrhea 24.4%) remaining problematic; regulatory pathway and competitive positioning against GLP-1 monotherapy warrants close monitoring through 2027 submission
Eli Lillyretatrutide
→ Read original articleClinical Trials•Endpoints News•Jul 23, 2026
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
background ▾
- •Retatrutide demonstrated the most powerful weight loss results among late-stage obesity candidates, with two Phase 3 wins supporting an early 2025 regulatory filing
- •The triple agonist mechanism (GLP-1/GIP/glucagon) shows superior efficacy versus established dual agonists, positioning Lilly to capture significant market share in the expanding obesity space
- •Monitor the FDA review timeline, comparative efficacy data versus tirzepatide/semaglutide in head-to-head studies, and safety signals during regulatory evaluation
Eli Lillyretatrutide
→ Read original article